DUET: A Phase 2 Study Evaluating the Efficacy and Safety of Sparsentan in Patients with FSGS.

H, Trachtman; P, Nelson; S, Adler; KN, Campbell; A, Chaudhuri; VK, Derebail; G, Gambaro; L, Gesualdo; DS, Gipson; J, Hogan; K, Lieberman; B, Marder; KE, Meyers; E, Mustafa; J, Radhakrishnan; T, Srivastava; M, Stepanians; V, Tesar; O, Zhdanova; R, Komers

doi:10.1681/asn.2018010091

Public

DUET: A Phase 2 Study Evaluating the Efficacy and Safety of Sparsentan in Patients with FSGS.

Shared by NobleBlocks on Nov 1, 2018 • 12:00 AM UTC

Authors:

Trachtman H

Nelson P

Adler S

Abstract

<h4>Background</h4>We evaluated and compared the effects of sparsentan, a dual endothelin type A (ET<sub>A</sub>) and angiotensin II type 1 receptor antagonist, with those of the angiotensin II type 1 receptor antagonist irbesartan in patients with primary FSGS.<h4>Methods</h4>In this phase 2, rando...

Subject

Angiotensin II

Endothelin

Proteinuria

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!